Abivax: Net Loss Doubles but Cash Reserves Provide Visibility
French biotech company Abivax has announced its 2025 results, highlighted by a fundraising of EUR 597.2 million in July, boosting its cash reserves to EUR 530.4 million and ensuring funding visibility until the fourth quarter of 2027. Despite this financial strength, the company's net loss has doubled to EUR 336.1 million, reflecting increased research and development expenses in preparation for the commercial launch of its leading candidate, obefazimod.
Strong Financial Position from 2025 Funding
The financing is a highlight of Abivax's 2025 results. The public offering initiated on July 28, 2025, in the United States raised a gross amount of $700.3 million, equivalent to EUR 597.2 million after commissions and fees. Combined with previous liquidity, this capital injection brings the total cash, cash equivalents, and short-term investments to EUR 530.4 million as of December 31, 2025. The company also fully repaid its debts to Kreos Capital VII and Heights Capital Management during the fiscal year, reducing its financial liabilities to just EUR 1.9 million. Based on current operational assumptions, this financial foundation is expected to fund operations until the fourth quarter of 2027, providing a crucial strategic window for advancing clinical trials and commercial preparations.
Significant Increase in Net Loss in 2025
The worsening net loss of EUR 336.1 million in 2025, up from EUR 176.2 million in 2024, directly reflects an intensified development effort. Research and development expenses increased by EUR 31.2 million to reach EUR 177.8 million, accounting for 70.9% of operational expenses. This increase is driven by three main factors: an increase of EUR 13 million in chemistry, manufacturing, and controls costs in anticipation of the upcoming commercial launch; an additional EUR 10.2 million for the phase 2b Crohn's disease program; and EUR 4.1 million for new indications. Obefazimod accounts for 96.5% of the R&D expenditure. General and administrative expenses also rose by EUR 34.7 million to EUR 67.7 million, particularly due to stock-based compensation charges linked to the stock price increase in the second half of the year.
Data Monitoring Committee Supports Continued Program
On March 18, 2026, the independent data monitoring committee (DSMB) completed its review based on 100% of the randomized patients in the phase 3 ABTECT trial, with nearly 90% having completed the 44-week treatment period. No new safety signals were identified, supporting the continuation of the program. Main results are expected by the end of the second quarter of 2026. Concurrently, Abivax is restructuring its governance to face the commercial phase: Michael Nesrallah, with 20 years of experience in pharma and former head of the IBD franchise at Takeda, joins as Chief Commercial Officer; Keith Fournier and Maurus de la Rosa complete this reconfiguration by respectively leading international regulatory affairs and research. The departure of Didier Scherrer, Chief Scientific Officer for 17 years, marks the transition from a purely scientific phase to a commercial execution phase. The general assembly on May 11, 2026, will need to approve these changes. A major challenge for investors: Abivax must convert its financial flexibility into positive clinical results and commercial capability before its cash reserves are depleted.
